comparemela.com

Latest Breaking News On - Poster number - Page 2 : comparemela.com

Nucleix Demonstrates Potential of its PCR EpiCheck® Assay to Accurately Differentiate Between Small Cell Lung Cancer (SCLC) Subtypes

SAN DIEGO & REHOVOT, Israel, April 04, 2024 Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from a pilot study demonstrating the potential of a simple PCR assay based on EpiCheck® technology to accurately differentiate between small cell lung cancer (SCLC) subtypes. The Company is presenting the data in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, April 5-10

Caris Life Sciences to Showcase Research Highlighting the Clinical Value of Comprehensive Molecular Profiling at the American Association for Cancer Research Annual Meeting

Caris Life Sciences to Showcase Research Highlighting the Clinical Value of Comprehensive Molecular Profiling at the American Association for Cancer Research Annual Meeting
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

EISAI TO PRESENT DATA ON LECANEMAB and OTHER ALZHEIMER S DISEASE RESEARCH AT THE AD/PD™ 2024 ANNUAL MEETING

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest findings on lecanemab (U.S. brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD), at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™) from March 5-9 in Lisbon, Portugal, and virtually. The lecanemab data and additional research findings from Eis

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.